Barbara Ann Karmanos Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Barbara Ann Karmanos Cancer Institute sits in the top decile of US sponsors by registered trial count (#202 of 15,742 sponsors by registered trial count).
Barbara Ann Karmanos Cancer Institute: 139 sponsored US clinical trials, 16 recruiting.
Barbara Ann Karmanos Cancer Institute sponsors 139 registered US clinical trials on ClinicalTrials.gov, 16 of them currently recruiting, and 100 completed. 1 of these trials are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 4 trials.
Top-decile sponsor footprint
Barbara Ann Karmanos Cancer Institute ranks in the top decile of sponsors by registered trial count (#202 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
100 of 120 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
139 total, page 2 of 3
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
NCT01534143
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01468532
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
NCT01420874
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
NCT02037256
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
NCT01270880
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
NCT01246206
Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation
NCT01251952
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
NCT01205646
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
NCT01116232
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
NCT01147016
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
NCT01022138
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
NCT01051570
DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer
NCT00972023
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
NCT00984919
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
NCT00942422
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00938626
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
NCT00888654
Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors
NCT00914147
Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx
NCT00918762
Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules
NCT00906503
Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis
NCT00890617
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
NCT00691015
A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants
NCT00768118
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
NCT00897910
Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00559897
Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00541099
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
NCT00503841
Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel
NCT00499694
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
NCT00520767
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
NCT00020722
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
NCT00459121
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
NCT00482846
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
NCT01656304
Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
NCT00897247
A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
NCT00618826
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00438204
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors
NCT00369109
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
NCT00514215
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00301808
Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
NCT00303901
Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy
NCT00305747
Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
NCT00288028
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT00258245
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00376948
Identification of Biomarkers for Early Detection of Pancreatic Cancer
NCT00897494
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
NCT00248560
Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer
NCT00897741
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
NCT00217581
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
NCT00293384
Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors
NCT00872677
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 33 |
| Phase 2 | 66 |
| Phase 3 | 1 |
What is open in the Barbara Ann Karmanos Cancer Institute pipeline
16 recruiting of 139 indexed (12% open); 100 completed (72%).
Phase mix: 1 late (III/IV) vs 99 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Barbara Ann Karmanos Cancer Institute: open-pipeline peers nationwide
Peers matched on 139 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Barbara Ann Karmanos Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 139 trials (± recruiting share)
- Centers for Disease Control and Prevention · 139 trials · 2% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
- Shirley Ryan AbilityLab · 138 trials · 26% recruiting
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 138 trials · 3% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Abbott Diabetes Care · 12% recruiting · 26 trials
- Medtronic Vascular · 12% recruiting · 26 trials
- Midwest Center for Metabolic and Cardiovascular Research · 12% recruiting · 26 trials
- VA Connecticut Healthcare System · 12% recruiting · 26 trials
Related
What to do with this Barbara Ann Karmanos Cancer Institute page
139 registered trials is a research-attention snapshot, not an endorsement of Barbara Ann Karmanos Cancer Institute or any single study.
- 16 of Barbara Ann Karmanos Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Barbara Ann Karmanos Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Barbara Ann Karmanos Cancer Institute pipeline card: 139 registered trials from official public datasets.Report a data error.